Antipsychotic occupancy of dopamine receptors in schizophrenia.
about
The development, past achievements, and future directions of brain PETNeuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophreniaTriangulating perspectives on functional neuroimaging for disorders of mental healthSmoking in schizophrenic patients: A critique of the self-medication hypothesis.The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.Modeling of PET data in CNS drug discovery and development.Chemistry-based molecular signature underlying the atypia of clozapine.Biomarkers in development of psychotropic drugs.Concise review: the promise of human induced pluripotent stem cell-based studies of schizophrenia.Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010.Personalized medicine in psychiatry: problems and promises.Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study.A chemical genetic approach identifies piperazine antipsychotics as promoters of CNS neurite growth on inhibitory substrates.Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitroCariprazine in the treatment of schizophrenia: a proof-of-concept trialUse of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats.Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis.Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRIEstablishing test-retest reliability of an adapted [(18)F]fallypride imaging protocol in older people.Introduction to the special issue "Pharmacotherapies for the treatment of alcohol abuse and dependence" and a summary of patents targeting other neurotransmitter systems.Biomarkers: refining diagnosis and expediting drug development - reality, aspiration and the role of open innovation.Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia.Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects.Cross-reactivity of Antibodies Directed to the Gram-Negative Bacterium Neisseria gonorrhoeae With Heat Shock Protein 60 and ATP-Binding Protein Correlates to Reduced Mitochondrial Activity in HIBCPP Choroid Plexus Papilloma Cells.Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.Antibodies directed to Neisseria gonorrhoeae impair nerve growth factor-dependent neurite outgrowth in Rat PC12 cells.The Harms of Antipsychotic Drugs: Evidence from Key Studies.Derisking Psychiatric Drug Development: The NIMH's Fast Fail Program, A Novel Precompetitive Model.Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.Network-assisted investigation of antipsychotic drugs and their targets.Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates.The amphetamine sensitization model of schizophrenia symptoms and its effect on schedule-induced polydipsia in the rat.Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR.Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia.
P2860
Q27026331-5A248CC1-EB33-447F-8AD3-3394C6A8864DQ27026382-F07EF1B4-C015-4622-B6E6-880780258B58Q27497063-F35BC260-6B9E-441B-8397-82A7F9DC5DEBQ30416030-964D253A-EC08-45CE-9C43-241846B09969Q30437188-D634C1F6-9C14-4B52-90FD-E5AC90431E9FQ30453929-50D4604E-E704-41DE-B6DB-AE9808BA12E9Q30623699-0EF1E9D8-22B9-404B-8661-C3B0902713D7Q33707728-31CCE138-E225-4A01-98B6-E6CD53CF5076Q33993209-1C2AF894-FA90-454E-A005-B2B3461DE5B6Q34051160-859D05AA-FFCC-4778-9ED5-B9C1DDC6E687Q34418688-B23D0CED-CA83-4C04-AF66-1F7F90848881Q34726454-576756ED-443D-49A4-9C38-730DEC47254EQ35002529-C38A9C48-D043-40DB-894A-D6FDDDC7E6D2Q35847706-83616B4C-01DF-4F93-A497-FC404F4751C2Q35910290-B80774FE-0984-4348-BE0F-7104022BEE79Q35946867-3247E2F4-17EC-459B-999B-B1953867774CQ36059047-FA019D5B-A582-4837-97F5-08D11578AE87Q36109823-C1E4A103-FD98-4B19-B3D0-689361ACD4D6Q36279518-65D1BB5C-D570-4C3F-8DE2-B8E2080A002BQ36530048-42D5F942-850A-46F2-AFCC-9C717FFD7002Q36787823-5402F1C8-793A-469D-B220-95718168AA31Q36955877-65E1F0DA-B183-477A-9073-55093B6C1555Q36990782-F86FA65D-53B5-48A7-ADBC-39A0327A1311Q36994341-5C162770-6AC0-47D9-80ED-CCE6C65AFA21Q37404222-F4BA0BE4-C3E6-4EDA-BE2F-12AD6E74D2E2Q38194173-0F1B5889-3BDE-413C-8108-4C09F4C141B6Q38239613-231DFCD3-318C-4C98-B06F-A9A88EE0BD9CQ38496254-8D0D8E69-7DFF-4E08-99B1-8C95DE6AFD59Q38775836-1A925634-61EF-45FF-A998-9BB1EC142AE1Q38863427-702ADCEF-02C9-4CC0-AF0E-DDC220EEFBC9Q38997108-9EDBECEA-CBBF-4070-9CFE-6811B0F39EE9Q39319258-0F20CCC7-C9C6-437D-B6D9-D022AF5C953EQ40467111-7FE6DBCD-B5F6-4C4C-97ED-63AF408CE350Q41647321-8A3B179B-93C8-42A0-839B-D6CDF9B25BCFQ41993974-D8B00D43-FA6A-40D6-BC44-7BC9DEE46A76Q43836810-E6ED9F76-7C8D-43CD-9C2D-F4BF9E02CEAAQ44255978-0F6C6090-228D-4121-9441-22CA917AD08EQ44600763-A16D3AE0-94B8-4052-8AA3-115DED79C134Q45786962-C011BBCB-290D-42B8-BCAE-BAC029C68D5EQ47098182-FEEC6C53-7041-461F-BD4C-67E712845A29
P2860
Antipsychotic occupancy of dopamine receptors in schizophrenia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antipsychotic occupancy of dopamine receptors in schizophrenia.
@en
Antipsychotic occupancy of dopamine receptors in schizophrenia.
@nl
type
label
Antipsychotic occupancy of dopamine receptors in schizophrenia.
@en
Antipsychotic occupancy of dopamine receptors in schizophrenia.
@nl
prefLabel
Antipsychotic occupancy of dopamine receptors in schizophrenia.
@en
Antipsychotic occupancy of dopamine receptors in schizophrenia.
@nl
P2860
P1476
Antipsychotic occupancy of dopamine receptors in schizophrenia.
@en
P2093
Lars Farde
Magdalena Nord
P2860
P304
P356
10.1111/J.1755-5949.2010.00222.X
P577
2010-12-08T00:00:00Z